Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 300 shares, a decline of 82.4% from the August 15th total of 1,700 shares. Based on an average daily volume of 4,200 shares, the days-to-cover ratio is currently 0.1 days.

Clinuvel Pharmaceuticals Trading Up 0.5 %

Shares of Clinuvel Pharmaceuticals stock traded up $0.05 on Thursday, reaching $9.90. 304 shares of the stock were exchanged, compared to its average volume of 2,795. Clinuvel Pharmaceuticals has a 1-year low of $8.42 and a 1-year high of $12.06. The business has a fifty day moving average price of $9.73 and a two-hundred day moving average price of $9.75.

Clinuvel Pharmaceuticals Increases Dividend

The company also recently declared a dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a dividend of $0.0299 per share. This is a positive change from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date is Monday, September 9th.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).